BostonGene CEO Andrew Feinberg to Deliver Keynote at Mobile World Congress Barcelona 2026

0
4

WALTHAM, Mass. — BostonGene said its President and Chief Executive Officer Andrew Feinberg will deliver a main stage keynote address at Mobile World Congress Barcelona 2026, one of the world’s largest global technology gatherings.

Feinberg is scheduled to speak on Tuesday, March 3, at the Barcelona-based conference, which attracts more than 100,000 industry leaders from across the global technology ecosystem. The event focuses on areas including artificial intelligence, digital ecosystems, and cross-industry innovation.

His keynote, titled “The Intelligence Dividend: Governing AI at Scale,” will examine how artificial intelligence is reshaping high-impact industries ranging from precision oncology and drug development to global telecommunications infrastructure. Drawing on his experience leading AI deployment in both complex biological systems and large-scale network environments, Feinberg is expected to focus on the importance of governance, transparency, and human oversight as AI adoption accelerates.

“The convergence of AI and life sciences is establishing the standards that the global tech ecosystem must now adopt,” said Surbhi Gupta, industry principal at Frost & Sullivan. “Applying AI in oncology demands a level of rigor and accountability that is rare in other sectors. BostonGene CEO Andrew Feinberg brings a unique cross-sector perspective on AI and can discuss how responsibly scaling AI drives positive impact across life sciences and telecom. This discipline will increasingly define AI leadership on a global scale.”

BostonGene develops an AI platform that integrates multimodal biological data to support pharmaceutical research, improve clinical trial design, and advance precision oncology. The company works with global biopharmaceutical partners and leading cancer centers to apply artificial intelligence in ways that improve therapeutic outcomes and reduce development risk.

According to the company, Feinberg’s address will outline how lessons learned from applying AI in oncology and drug development can serve as a blueprint for deploying artificial intelligence safely and effectively across a wide range of industries.

Leave A Reply

Please enter your comment!
Please enter your name here